Cargando…
Contribution of hypoxia inducible factor-1 during viral infections
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that plays critical roles during the cellular response to hypoxia. Under normoxic conditions, its function is tightly regulated by the degradation of its alpha subunit (HIF-1α), which impairs the formation of an active heterodimer in the n...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605355/ https://www.ncbi.nlm.nih.gov/pubmed/33135539 http://dx.doi.org/10.1080/21505594.2020.1836904 |
_version_ | 1783604292675960832 |
---|---|
author | Reyes, Antonia Corrales, Nicolás Gálvez, Nicolás M. S. Bueno, Susan M. Kalergis, Alexis M. González, Pablo A. |
author_facet | Reyes, Antonia Corrales, Nicolás Gálvez, Nicolás M. S. Bueno, Susan M. Kalergis, Alexis M. González, Pablo A. |
author_sort | Reyes, Antonia |
collection | PubMed |
description | Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that plays critical roles during the cellular response to hypoxia. Under normoxic conditions, its function is tightly regulated by the degradation of its alpha subunit (HIF-1α), which impairs the formation of an active heterodimer in the nucleus that otherwise regulates the expression of numerous genes. Importantly, HIF-1 participates in both cancer and infectious diseases unveiling new therapeutic targets for those ailments. Here, we discuss aspects related to the activation of HIF-1, the effects of this transcription factor over immune system components, as well as the involvement of HIF-1 activity in response to viral infections in humans. Although HIF-1 is currently being assessed in numerous clinical settings as a potential therapy for different diseases, up to date, there are no clinical studies evaluating the pharmacological modulation of this transcription factor as a possible new antiviral treatment. However, based on the available evidence, clinical trials targeting this molecule are likely to occur soon. In this review we discuss the role of HIF-1 in viral immunity, the modulation of HIF-1 by different types of viruses, as well as the effects of HIF-1 over their life cycle and the potential use of HIF-1 as a new target for the treatment of viral infections. |
format | Online Article Text |
id | pubmed-7605355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-76053552020-11-12 Contribution of hypoxia inducible factor-1 during viral infections Reyes, Antonia Corrales, Nicolás Gálvez, Nicolás M. S. Bueno, Susan M. Kalergis, Alexis M. González, Pablo A. Virulence Review Article Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that plays critical roles during the cellular response to hypoxia. Under normoxic conditions, its function is tightly regulated by the degradation of its alpha subunit (HIF-1α), which impairs the formation of an active heterodimer in the nucleus that otherwise regulates the expression of numerous genes. Importantly, HIF-1 participates in both cancer and infectious diseases unveiling new therapeutic targets for those ailments. Here, we discuss aspects related to the activation of HIF-1, the effects of this transcription factor over immune system components, as well as the involvement of HIF-1 activity in response to viral infections in humans. Although HIF-1 is currently being assessed in numerous clinical settings as a potential therapy for different diseases, up to date, there are no clinical studies evaluating the pharmacological modulation of this transcription factor as a possible new antiviral treatment. However, based on the available evidence, clinical trials targeting this molecule are likely to occur soon. In this review we discuss the role of HIF-1 in viral immunity, the modulation of HIF-1 by different types of viruses, as well as the effects of HIF-1 over their life cycle and the potential use of HIF-1 as a new target for the treatment of viral infections. Taylor & Francis 2020-10-31 /pmc/articles/PMC7605355/ /pubmed/33135539 http://dx.doi.org/10.1080/21505594.2020.1836904 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Reyes, Antonia Corrales, Nicolás Gálvez, Nicolás M. S. Bueno, Susan M. Kalergis, Alexis M. González, Pablo A. Contribution of hypoxia inducible factor-1 during viral infections |
title | Contribution of hypoxia inducible factor-1 during viral infections |
title_full | Contribution of hypoxia inducible factor-1 during viral infections |
title_fullStr | Contribution of hypoxia inducible factor-1 during viral infections |
title_full_unstemmed | Contribution of hypoxia inducible factor-1 during viral infections |
title_short | Contribution of hypoxia inducible factor-1 during viral infections |
title_sort | contribution of hypoxia inducible factor-1 during viral infections |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605355/ https://www.ncbi.nlm.nih.gov/pubmed/33135539 http://dx.doi.org/10.1080/21505594.2020.1836904 |
work_keys_str_mv | AT reyesantonia contributionofhypoxiainduciblefactor1duringviralinfections AT corralesnicolas contributionofhypoxiainduciblefactor1duringviralinfections AT galveznicolasms contributionofhypoxiainduciblefactor1duringviralinfections AT buenosusanm contributionofhypoxiainduciblefactor1duringviralinfections AT kalergisalexism contributionofhypoxiainduciblefactor1duringviralinfections AT gonzalezpabloa contributionofhypoxiainduciblefactor1duringviralinfections |